Elia Seguí
Impact in
-
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
-
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
Papers in
- Oncology 16
- COVID-19 and healthcare impacts 5
- Cancer Immunotherapy and Biomarkers 5
- Inflammatory Biomarkers in Disease Prognosis 4
- HER2/EGFR in Cancer Research 3
- Cancer Treatment and Pharmacology 2
-
- Advanced Breast Cancer Therapies 4
- Co-authors
- Joan Padrosa (3 shared papers)Francesco Schettini (4 shared papers)Javier Marco‐Hernández (3 shared papers)Aleix Prat (8 shared papers)Alba Di Leone (1 shared paper)Alessandra Fabi (1 shared paper)Eugene F. Schuster (1 shared paper)María Vidal (3 shared papers)
- Journals
- Annals of Oncology (5 papers)Journal of Clinical Oncology (3 papers)Cancers (1 paper)Frontiers in Oncology (1 paper)ESMO Open (1 paper)
- Partner nations
- SpainItalyUnited States
In The Last Decade
Elia Seguí
15 papers receiving 61 citations
Peers
Comparison fields: 5 of 30
- Cancer Research 22
- Oncology 38
- Pulmonary and Respiratory Medicine 21
- Immunology 10
- Genetics 5
Countries citing papers authored by Elia Seguí
This map shows the geographic impact of Elia Seguí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elia Seguí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elia Seguí more than expected).
Fields of papers citing papers by Elia Seguí
This network shows the impact of papers produced by Elia Seguí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elia Seguí. The network helps show where Elia Seguí may publish in the future.
Co-authors
The 25 scholars most cited alongside Elia Seguí, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 12 | |
| 2 | 2021 | 9 | |
| 3 | 2022 | 9 | |
| 4 | 2023 | 8 | |
| 5 | 2022 | 4 | |
| 6 | 2024 | 3 | |
| 7 | 2020 | 3 | |
| 8 | 2022 | 3 | |
| 9 | 2021 | 3 | |
| 10 | 2024 | 2 | |
| 11 | 2024 | 1 | |
| 12 | 2024 | 1 | |
| 13 | 2020 | 1 | |
| 14 | 2025 | 1 | |
| 15 | [Postpartum hemolytic uremic syndrome: a rare entity and a treatment challenge]. | 2008 | 1 |
| 16 | 2020 | 0 | |
| 17 | 2022 | 0 | |
| 18 | 2020 | 0 | |
| 19 | 2021 | 0 |
About Elia Seguí
Elia Seguí is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics and Infectious Diseases, having authored 19 papers that have together received 61 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (5 papers), COVID-19 and healthcare impacts (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers), Advanced Breast Cancer Therapies (4 papers), HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Cancer Research (22 citations), Oncology (38 citations), Pulmonary and Respiratory Medicine (21 citations), Immunology (10 citations) and Genetics (5 citations). Elia Seguí has collaborated with scholars based in Spain, Italy and United States. Frequent co-authors include Joan Padrosa, Francesco Schettini, Javier Marco‐Hernández, Aleix Prat, Alba Di Leone, Alessandra Fabi, Eugene F. Schuster, María Vidal, Mitch Dowsett and Montserrat Muñoz-Mateu. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Cancers, Frontiers in Oncology and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.